The Management of Individuals with Bipolar Disorder A Review of the Evidence and its Integration into Clinical Practice

被引:42
作者
Malhi, Gin S. [1 ,2 ]
Adams, Danielle [1 ,3 ]
Cahill, Catherine M. [1 ,2 ,4 ]
Dodd, Seetal [5 ]
Berk, Michael [5 ,6 ,7 ,8 ]
机构
[1] Royal N Shore Hosp, Dept Psychiat, CADE Clin, Sydney, NSW 2065, Australia
[2] Univ Sydney, Acad Discipline Psychol Med, No Clin Sch, Sydney, NSW 2006, Australia
[3] No Sydney Cent Coast Mental Hlth & Drug & Alcohol, Sydney, NSW, Australia
[4] Westmead Hosp, Traumat Stress Clin, Sydney, NSW, Australia
[5] Univ Melbourne, Dept Clin & Biomed Sci Barwon Hlth, Geelong, Vic, Australia
[6] Healthscope, Geelong Clin, Geelong, Vic, Australia
[7] Mental Hlth Res Inst, Melbourne, Vic, Australia
[8] Orygen Res Ctr, Melbourne, Vic, Australia
基金
澳大利亚国家健康与医学研究理事会;
关键词
SEROTONIN-REUPTAKE INHIBITORS; LITHIUM MAINTENANCE TREATMENT; PLACEBO-CONTROLLED TRIAL; COGNITIVE-BEHAVIORAL THERAPY; FAMILY-FOCUSED TREATMENT; TRANSCRANIAL MAGNETIC STIMULATION; RELEASE CARBAMAZEPINE CAPSULES; RANDOMIZED CONTROLLED-TRIAL; ANXIETY TREATMENTS CANMAT; CONTROLLED 18-MONTH TRIAL;
D O I
10.2165/11318850-000000000-00000
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Bipolar disorder is a common, debilitating, chronic illness that emerges early in life and has serious consequences such as long-term unemployment and suicide. It confers considerable functional disability to the individual, their family and society as a whole and yet it is often undetected, misdiagnosed and treated poorly. In the past decade, many new treatment strategies have been trialled in the management of bipolar disorder with variable success. The emerging evidence, for pharmacological agents in particular, is promising but when considered alone does not directly translate to real-world clinical populations of bipolar disorder. Data from drug trials are largely based on findings that identify differences between groups determined in a time-limited manner, whereas clinical management concerns the treatment of individuals over the life-long course of the illness. Considering the findings in the context of the individual and their particular needs perhaps best bridges the gap between the evidence from research studies and their application in clinical practice. Specifically, only lithium and valproate have moderate or strong evidence for use across all three phases of bipolar disorder. Anticonvulsants, such as lamotrigine, have strong evidence in maintenance; whereas antipsychotics largely have strong evidence in acute mania, with the exception of quetiapine, which has strong evidence in bipolar depression. Maintenance data for antipsychotics is emerging but at present remains weak. Combinations have strong evidence in acute phases of illness but maintenance data is urgently needed. Conventional antidepressants only have weak evidence in bipolar depression and do not have a role in maintenance therapy. Therefore, this paper summarizes the efficacy data for treating bipolar disorder and also applies clinical considerations to these data when formulating recommendations for the management of bipolar disorder.
引用
收藏
页码:2063 / 2101
页数:39
相关论文
共 377 条
[1]  
ACOG Committee on Practice Bulletins--Obstetrics, 2008, Obstet Gynecol, V111, P1001, DOI 10.1097/AOG.0b013e31816fd910
[2]   Efficacy and safety of antidepressant monotherapy in the treatment of bipolar-II depression [J].
Agosti, Vito ;
Stewart, Jonathan W. .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2007, 22 (05) :309-311
[3]   Validating 'hard' and 'soft' phenotypes within the bipolar spectrum: continuity or discontinuity? [J].
Akiskal, HS .
JOURNAL OF AFFECTIVE DISORDERS, 2003, 73 (1-2) :1-5
[4]   The evolving bipolar spectrum - Prototypes I, II, III, and IV [J].
Akiskal, HS ;
Pinto, O .
PSYCHIATRIC CLINICS OF NORTH AMERICA, 1999, 22 (03) :517-+
[5]   Adjunctive long-acting risperidone delays mood episode relapse in patients with frequently relapsing bipolar disorder [J].
Alphs, L. ;
Haskins, J. T. ;
Turkoz, I. ;
Turner, N. ;
Schreiner, A. ;
Macfadden, W. .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 :S441-S442
[6]   Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects [J].
Alwan, Sura ;
Reefhuis, Jennita ;
Rasmussen, Sonja A. ;
Olney, Richard S. ;
Friedman, Jan M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (26) :2684-2692
[8]   Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode - A randomized open-label study [J].
Amsterdam, Jay D. ;
Shults, Justine .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2008, 28 (02) :171-181
[9]  
Amsterdam JD, 2000, J AFFECT DISORDERS, V59, P225, DOI 10.1016/S0165-0327(99)00149-4
[10]   Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression - lack of manic induction [J].
Amsterdam, JD ;
Shults, J .
JOURNAL OF AFFECTIVE DISORDERS, 2005, 87 (01) :121-130